In recent years, the debate over net price transparency (NPT) has intensified with organisations leading calls for greater transparency of net prices in the pharmaceutical sector. In a study funded by Merck Sharp & Dohme, an expert panel coordinated by CRA developed evidence on the impact of greater NPT on innovative medicines in Europe.
Know your customer: Strategic considerations for AI-powered provider segmentation
Published in Life Science Leader, CRA’s Robert Broadnax, Eddie Li and Brian Carpenter co-authored an article “Know Your Customer: Strategic Considerations for...